{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:17:25Z","timestamp":1794647845340,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01081-3","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:02:07Z","timestamp":1767348127000},"page":"116-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The MEK\u2013RAF molecular glue IK-595 has potent antitumor activity across RAS\/MAPK pathway-altered cancers"],"prefix":"10.1038","volume":"7","author":[{"given":"Eric","family":"Haines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Catterall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Wessell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sanchez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ivliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmin","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Santillana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4232-5490","authenticated-orcid":false,"given":"Jeffrey","family":"Ecsedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine K.","family":"Ruppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan, M. B. & Corcoran, R. B. Therapeutic strategies to target RAS-mutant cancers. Nat. Rev. Clin. Oncol. 15, 709\u2013720 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1081_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cells10102509","volume":"10","author":"R Sugiura","year":"2021","unstructured":"Sugiura, R., Satoh, R. & Takasaki, T. ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells 10, 2509 (2021).","journal-title":"Cells"},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/1873-3468.12740","volume":"591","author":"EB Unal","year":"2017","unstructured":"Unal, E. B., Uhlitz, F. & Bluthgen, N. A compendium of ERK targets. FEBS Lett. 591, 2607\u20132615 (2017).","journal-title":"FEBS Lett."},{"key":"1081_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","unstructured":"AACR Project GENIE Consortium AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818\u2013831 (2017).","journal-title":"Cancer Discov."},{"key":"1081_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrc2109","volume":"7","author":"S Schubbert","year":"2007","unstructured":"Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295\u2013308 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"1081_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T. et al. Mechanism of activation of the RAF\u2013ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855\u2013867 (2004).","journal-title":"Cell"},{"key":"1081_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/0008-5472.CAN-13-2381","volume":"74","author":"X Deschenes-Simard","year":"2014","unstructured":"Deschenes-Simard, X., Kottakis, F., Meloche, S. & Ferbeyre, G. ERKs in cancer: friends or foes? Cancer Res. 74, 412\u2013419 (2014).","journal-title":"Cancer Res."},{"key":"1081_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger, R. & Corcoran, R. B. Targeting alterations in the RAF\u2013MEK pathway. Cancer Discov. 9, 329\u2013341 (2019).","journal-title":"Cancer Discov."},{"key":"1081_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","volume":"91","author":"S Bamford","year":"2004","unstructured":"Bamford, S. et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br. J. Cancer 91, 355\u2013358 (2004).","journal-title":"Br. J. Cancer"},{"key":"1081_CR10","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","volume":"35","author":"JC Jones","year":"2017","unstructured":"Jones, J. C. et al. Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J. Clin. Oncol. 35, 2624\u20132630 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1081_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1535370220959657","volume":"246","author":"J Owsley","year":"2021","unstructured":"Owsley, J. et al. Prevalence of class I\u2013III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp. Biol. Med. (Maywood) 246, 31\u201339 (2021).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"1081_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710 (2014).","journal-title":"Cancer Cell"},{"key":"1081_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110351","volume":"38","author":"A Venkatanarayan","year":"2022","unstructured":"Venkatanarayan, A. et al. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep. 38, 110351 (2022).","journal-title":"Cell Rep."},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1038\/s41586-020-2760-4","volume":"588","author":"ZM Khan","year":"2020","unstructured":"Khan, Z. M. et al. Structural basis of the action of the drug trametinib at KSR-bound MEK. Nature 588, 7838 (2020).","journal-title":"Nature"},{"key":"1081_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0139","volume":"14","author":"MB Ryan","year":"2024","unstructured":"Ryan, M. B. et al. The Pan-RAF\u2013MEK nondegrading molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS\u2013MAPK pathway with activity across diverse RAS- and RAF-driven cancers. Cancer Discov. 14, 7 (2024).","journal-title":"Cancer Discov."},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante, J. R. et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 13, 773\u2013781 (2012).","journal-title":"Lancet Oncol."},{"key":"1081_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01552-6","volume":"4","author":"M Sinkala","year":"2021","unstructured":"Sinkala, M., Nkhoma, P., Mulder, N. & Martin, D. P. Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies. Commun. Biol. 4, 9 (2021).","journal-title":"Commun. Biol."},{"key":"1081_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/cancers15010141","volume":"15","author":"M Garutti","year":"2022","unstructured":"Garutti, M. et al. BRAF and MEK inhibitors and their toxicities: a meta-analysis. Cancers (Basel) 15, 141 (2022).","journal-title":"Cancers (Basel)"},{"key":"1081_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-023-04544-5","volume":"92","author":"DW Rasco","year":"2023","unstructured":"Rasco, D. W. et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother. Pharmacol. 92, 15\u201328 (2023).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1081_CR20","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/cancers13092010","volume":"13","author":"G Awada","year":"2021","unstructured":"Awada, G. et al. A phase 2 clinical trial of trametinib and low-dose dabrafenib in patients with advanced pretreated NRASQ61R\/K\/L mutant melanoma (TraMel-WT). Cancers (Basel) 13, 2010 (2021).","journal-title":"Cancers (Basel)"},{"key":"1081_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","volume":"594","author":"I Yen","year":"2021","unstructured":"Yen, I. et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature 594, 418\u2013423 (2021).","journal-title":"Nature"},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-13-0011","volume":"12","author":"MS Carlino","year":"2013","unstructured":"Carlino, M. S. et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and\/or MEK inhibition in melanoma. Mol. Cancer Ther. 12, 1332\u20131342 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1081_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6694","volume":"5","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).","journal-title":"Nat. Commun."},{"key":"1081_CR24","unstructured":"Center for Drug Evaluation and Research. Clinical Pharmacology and Biotherapeutics Review. Application number: 204114Orig1s000. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204114orig1s000clinpharmr.pdf (2013)."},{"key":"1081_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","volume":"30","author":"MI Barbato","year":"2024","unstructured":"Barbato, M. I. et al. FDA approval summary: dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma. Clin. Cancer Res. 30, 263\u2013268 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey, D. et al. FDA approval summary: selumetinib for plexiform neurofibroma. Clin. Cancer Res. 27, 4142\u20134146 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1081_CR27","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AKS Salama","year":"2020","unstructured":"Salama, A. K. S. et al. Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H. J. Clin. Oncol. 38, 3895\u20133904 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1081_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5907-7","volume":"19","author":"S Guo","year":"2019","unstructured":"Guo, S., Jiang, X., Mao, B. & Li, Q. X. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer 19, 718 (2019).","journal-title":"BMC Cancer"},{"key":"1081_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan, M. B. et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39, 110993 (2022).","journal-title":"Cell Rep."},{"key":"1081_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek, T. J. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023).","journal-title":"Nat. Cancer"},{"key":"1081_CR31","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","volume":"27","author":"KA Monaco","year":"2021","unstructured":"Monaco, K. A. et al. LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors. Clin. Cancer Res. 27, 2061\u20132073 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1081_CR32","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","volume":"18","author":"M Martinez-Garcia","year":"2012","unstructured":"Martinez-Garcia, M. et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 18, 4806\u20134819 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1081_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molcel.2005.10.022","volume":"20","author":"MJ Garnett","year":"2005","unstructured":"Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963\u2013969 (2005).","journal-title":"Mol. Cell"},{"key":"1081_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234\u2013238 (2017).","journal-title":"Nature"},{"key":"1081_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","volume":"2","author":"KB Dahlman","year":"2012","unstructured":"Dahlman, K. B. et al. BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791\u2013797 (2012).","journal-title":"Cancer Discov."},{"key":"1081_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim, K. B. et al. Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482\u2013489 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1081_CR37","doi-asserted-by":"publisher","first-page":"9483","DOI":"10.1158\/0008-5472.CAN-05-4227","volume":"66","author":"N Dumaz","year":"2006","unstructured":"Dumaz, N. et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483\u20139491 (2006).","journal-title":"Cancer Res."},{"key":"1081_CR38","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01081-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01081-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:02:24Z","timestamp":1769785344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01081-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01081-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are previous employees and shareholders of Ikena Oncology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}